Drugs / OPV
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02062385 | May 2014 → Jun 2015 | Rotavirus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OPV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02062385 ↗ |
| Known as | tOPV | “Trivalent oral poliovirus vaccine (tOPV) and diphtheria, tetanus, and acellular pertussis vaccine (DTaP) were administered in a staggered-use (N = 3,240) or concomitant-use...” PMID 30808567 ↗ Feb 2019 |
| Modality | Vaccine | “Oral poliovirus vaccine administered according to the standard of care” NCT02062385 ↗ |
| Route | Oral | “Oral poliovirus vaccine (OPV) administered as a 1 g oral solution” NCT02062385 ↗ |